Combination therapy can improve the efficacy of immunotherapy by relieving high interstitial pressure, increasing the infiltration of immune cells, enhancing the response to IFN-γ, and upregulating the MHC-I expression in tumor cells (198). The gene discussed is IFNG; the disease is neoplasm.